Sort   by:  
 Page size 
TranscriptomicsRNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates Fasudil as an anti-leukemic drug.
Acute myeloid leukemia (AML) is characterized by a marked genetic heterogeneity, which complicates the development of novel therapeutics. The delineation of pathways essential within the patient-individual mutational background might overcome this limitation and facilitate personalized treatment. We...
ORGANISM(S): Homo sapiens 
2015-05-16 | E-GEOD-68925 | biostudies-arrayexpress
TranscriptomicsRescue of murine Gata1s mutant M7 leukemic cells by full-length Gata1
In this project, we studied a mouse model of human Down Syndrome (DS) megakaryocytic leukemia involving mutations in the GATA1 transcription factor (called GATA1s mutation). The model was generated through retroviral insertional mutagenesis in Gata1s mutant fetal liver progenitors. In this study, we...
ORGANISM(S): Mus musculus 
2010-08-01 | E-GEOD-16676 | biostudies-arrayexpress
TranscriptomicsBraf inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia, and exert anti-leukemic activity
Hairy cell leukemia (HCL) shows unique clinico-pathological and biological features. HCL responds well to purine analogues but relapses are frequent and novel therapies are required. BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-cell lymphomas, including HCL-like leu...
ORGANISM(S): Homo sapiens 
2014-12-12 | E-GEOD-63790 | biostudies-arrayexpress
GenomicsEpigenetic profiling of WT and Ezh2-null MLL-AF9 murine leukemic cells
Chromatin immunoprecipitation (ChIP) for H3K27me3 followed by Solexa sequencing in WT and Ezh2-null leukemic cells from primary and secondary recipients. Leukemic cells from primary and secondary recipients of MLL-AF9-transduced WT and Ezh2-null cells were sorted for GFP and YFP expression and analy...
ORGANISM(S): Mus musculus 
2012-02-22 | E-GEOD-34962 | biostudies-arrayexpress
TranscriptomicsAffymetrix gene arrays of leukemic BM samples from 24 mice including 9 primary
To identify such targets of leukemia-related miRNAs such as miR-196b, we conducted Affymetrix gene arrays of leukemic BM samples from 24 mice including 9 primary (including 3 each of negative control, MLL-AF9, and miR-196b+MLL-AF9) and 15 secondary (including 3 negative control, 6 MLL-AF9, and 6 miR...
ORGANISM(S): Mus musculus 
2012-08-09 | E-GEOD-34185 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human chromic myeloid leukemia (CML) patients treated second-line with imatinib after failure of an interferon-alpha based therapy to identify genes with predictive value for primary cytogenetic outcome to imatinib
Identification of genes in CML patients with predictive value for their primary cytogenetic outcome to imatinib. All samples analyzed were taken just before the start of imatinib treatment. Leukemic patients were treated second-line with imatinib after failure of an interferon-alpha based therapy (f...
ORGANISM(S): Homo sapiens 
2006-05-31 | E-MEXP-433 | biostudies-arrayexpress
TranscriptomicsDNA sequencing comparing different stages of leukemic progression in a mouse model of severe congenital neutropenia (SCN)
To address how Csf3r and RUNX1 mutations in combination with CSF3 administration affect hematopoiesis in vivo, we performed serial transplantation experiments. Lineage-negative Csfr-d715 BM cell cells were lentivirally transduced with the patient specific RUNX1-D171N (RHD) mutant or an empty vector ...
ORGANISM(S): Mus musculus 
2020-08-24 | E-MTAB-9376 | biostudies-arrayexpress
TranscriptomicsPromiscuous targeting of bromodomains by Bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia [set2]
Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of selective and potent BET inhibitors and their significant activity in diverse tumor models has rapidly translated into clinical studies and has motivated drug development efforts targeting non-BET BRDs. How...
ORGANISM(S): Homo sapiens 
2016-10-25 | E-GEOD-78829 | biostudies-arrayexpress
GenomicsMutated H3 Histones Drive Human Pre-Leukemic Hematopoietic Stem Cell Expansion And Promote Leukemic Aggressiveness
Mutated H3 Histones Drive Human Pre-Leukemic Hematopoietic Stem Cell Expansion And Promote Leukemic Aggressiveness
PRJNA504437 | ENA
TranscriptomicsPromiscuous targeting of bromodomains by Bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia [set 1]
Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of selective and potent BET inhibitors and their significant activity in diverse tumor models has rapidly translated into clinical studies and has motivated drug development efforts targeting non-BET BRDs. How...
ORGANISM(S): Homo sapiens 
2016-10-25 | E-GEOD-78827 | biostudies-arrayexpress
Sort   by:  
 Page size